Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02507011 · ClinicalTrials.gov registry record · Phase 2
Beta-blockers in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02507011 is a Phase 2 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 2 participants.
The verdict
NCT02507011, a Phase 2 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.
Interventions
- DRUG Placebo
- DRUG Carvedilol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-01-31 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02507011
The ClinicalTrials.gov registry entry for NCT02507011 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02507011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02507011 about?
NCT02507011 is a clinical study titled "Beta-blockers in Pulmonary Arterial Hypertension". The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.
What is the current status of trial NCT02507011?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2016-01-31. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT02507011?
The interventions under investigation include: Placebo (DRUG), Carvedilol (DRUG).
Who is sponsoring clinical trial NCT02507011?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.